Kyowa Kirin (4151.T)

Executive Summary

Kyowa Kirin is a global specialty pharmaceutical company headquartered in Tokyo, Japan, with a focus on innovative antibody therapeutics, recombinant proteins, and gene therapies. The company addresses unmet medical needs in bone & mineral diseases, hematologic malignancies, and rare diseases, leveraging its proprietary POTELLIGENT antibody technology and hematopoietic stem cell gene therapy platforms. With a presence in over 50 markets and 72% of revenue generated overseas, Kyowa Kirin has a diversified portfolio of approved products including KRN23 (burosumab) for tumor-induced osteomalacia and mogamulizumab for advanced solid tumors. The company’s pipeline is highlighted by KHK4951, a Phase 2 candidate for neovascular age-related macular degeneration (nAMD), with trial completion expected in September 2026. As a publicly traded company (4151.T) with a market capitalization of approximately ¥123 trillion, Kyowa Kirin is well-positioned for sustained growth through its robust R&D pipeline and global commercialization network.

Upcoming Catalysts (preview)

• Q3 2026KHK4951 Phase 2 Data Readout in nAMD60% success
• TBDPotential Regulatory Submission for Gene Therapy Program40% success
• H2 2026Annual R&D Day with Pipeline Updates100% success